Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Objectives: Agomelatine has been shown to be safe and efficient in the treatment of major depressive disorder at 25 mg daily. The aim of this study was to gather preliminary data regarding the antidepressant efficacy of agomelatine in patients with bipolar I disorder experiencing a major depressive episode. Methods: Bipolar I patients on lithium (n = 14) or valpromide (n = 7), with a Hamilton Rating Scale for Depression (HAM‐D‐17) total score ≥ 18, were given adjunctive open‐label agomelatine at 25 mg/day for a minimum of 6 weeks followed by an optional extension of up to an additional 46 weeks. Results: Using intent‐to‐treat data, 81% of patients met criteria for marked improvement (>50% improvement from baseline in HAM‐D score) at study endpoint. Patients were severely depressed at study entry (HAM‐D of 25.2) and 47.6% responded as early as at one week of treatment. Nineteen patients entered the optional extension period for a mean of 211 days (range 6–325 days). Eleven patients completed the one‐year extension on agomelatine. There were no dropouts due to adverse events during the acute phase of treatment (6 weeks). Six patients experienced serious adverse events during the one‐year period. Three lithium‐treated patients experienced manic or hypomanic episodes during the optional extension period, one of which was treatment‐related. Conclusions: These results indicate the effectiveness of agomelatine 25 mg in the treatment of depressed bipolar I patients co‐medicated with lithium or valpromide. A randomized controlled trial is planned to confirm these results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Souêtre, E., Salvati, E., Belugou, J.-L., Pringuey, D., Candito, M., Krebs, B., Ardisson, J.-L., & Darcourt, G. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90207-2 · Cited by 396
Melatonin analogues as agonists and antagonists in the circadian system and other brain areas
Ying, S.-W., Rusak, B., Delagrange, P., Mocaër, E., Renard, P., & Guardiola-Lemaître, B. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00684-2 · Cited by 114
Benedetti, F., Barbini, B., Campori, E., Fulgosi, M. C., Pontiggia, A., & Colombo, C. (2001) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(01)00034-6 · Cited by 110
Cited by
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“, 2013) and agomelatine has had mixed findings for the treatment of bipolar depression (Calabrese et al., 2007; Fornaro et al., 2013; Yatham, 2015).”
BackgroundMelatonin and its analogs in insomnia and depression
Cardinali, D. P., Srinivasan, V., Brzezinski, A., & Brown, G. M. (2012) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00962.x · Cited by 353
Harvey, A. G., Soehner, A. M., Kaplan, K. A., Hein, K., Lee, J., Kanady, J., Li, D., Rabe-Hesketh, S., Ketter, T. A., Neylan, T. C., et al. (2015) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0038655 · Cited by 257
Geoffroy, P. A., Bellivier, F., Scott, J., & Etain, B. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.07.002 · Cited by 251
The role of mitochondria in mood disorders: from physiology to pathophysiology and to treatment
Giménez-Palomo, A., Dodd, S., Anmella, G., Carvalho, A. F., Scaini, G., Quevedo, J., Pacchiarotti, I., Vieta, E., & Berk, M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.546801 · Cited by 140
Metadata
- Authors
- Calabrese, J. R., Guelfi, J. D., Perdrizet‐Chevallier, C., & the Agomelatine Bipolar Study Group
- Venue
- Bipolar Disorders
- Publisher
- Wiley
- Published
- 2007-09
- Volume
- 9
- Issue
- 6
- Pages
- 628-635
- ISSN
- 1398-5647 (ISSN-L)
- 1399-5618
- OpenAlex
- W2031809759
- Cited by
- 130
- References
- 3
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. https://app.cochat.ai/papers/10.1111/j.1399-5618.2007.00507.x
- The paper
- Calabrese, J. R., Guelfi, J. D., Perdrizet‐Chevallier, C., & the Agomelatine Bipolar Study Group. (2007). Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disorders. https://doi.org/10.1111/j.1399-5618.2007.00507.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.